Genolution Inc.
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more
Genolution Inc. - Asset Resilience Ratio
Genolution Inc. (225220) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Genolution Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Genolution Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩3.79 Billion | 3.8% |
| Total Liquid Assets | ₩3.79 Billion | 3.80% |
Asset Resilience Insights
- Limited Liquidity: Genolution Inc. maintains only 3.80% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Genolution Inc. Industry Peers by Asset Resilience Ratio
Compare Genolution Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Genolution Inc. (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Genolution Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.20% | ₩33.21 Billion | ₩106.45 Billion | -6.49pp |
| 2023-12-31 | 37.69% | ₩42.75 Billion | ₩113.44 Billion | -2.82pp |
| 2022-12-31 | 40.51% | ₩46.37 Billion | ₩114.45 Billion | -7.87pp |
| 2021-12-31 | 48.38% | ₩45.93 Billion | ₩94.94 Billion | -10.06pp |
| 2020-12-31 | 58.44% | ₩48.96 Billion | ₩83.77 Billion | +30.02pp |
| 2019-12-31 | 28.42% | ₩3.82 Billion | ₩13.43 Billion | -18.57pp |
| 2018-12-31 | 46.99% | ₩5.21 Billion | ₩11.10 Billion | +1.21pp |
| 2017-12-31 | 45.78% | ₩2.15 Billion | ₩4.71 Billion | -12.50pp |
| 2016-12-31 | 58.28% | ₩2.33 Billion | ₩3.99 Billion | -- |